Skip to main content

Table 3 Obstetric outcomes and maternal side effects associated with airway device. Values are presented as frequency (%), mean (SD) and median [IQR, min-max]

From: Supreme™ laryngeal mask airway use in general Anesthesia for category 2 and 3 Cesarean delivery: a prospective cohort study

Characteristic

All Parturients n = 584

Category 2 Parturientsn = 193

Category 3 Parturients n = 391

Effect measure (95%CI)

P - value

Neonatal weight (kg), mean (SD)a

3.0 (0.5)

2.7 (0.5)

3.2 (0.4)

0.51 (0.42, 0.60)

<0.0001

Neonatal APGAR 1 min, median [IQR, min-max]b

9 [9–10, 3–10]

9 [8–10, 3–10]

10 [9–10, 7–10]

<0.0001

Neonatal APGAR 5 min, median [IQR, min-max]b

10 [10–10, 5–10]

10 [9–10, 5–10]

10 [10–10, 8–10]

<0.0001

Neonatal venous cord pH, mean (SD)a

7.3 (0.1)

7.3 (0.1)

7.3 (0.1)

0.003 (−0.01, 0.01)

0.5495

Presence of blood on SLMA, n (%)c

8 (1.4)

7 (3.6)

1 (0.3)

−0.03 (0.05, −0.12)

0.0023

Sore throat, n (%)c

38 (6.5)

14 (7.3)

24 (6.1)

−0.01 (0.08, −0.10)

0.5970

Hoarseness, n (%)c

4 (0.7)

0 (0.0)

4 (1.0)

0.01 (0.10, −0.08)

0.3077

Maternal satisfaction, mean (SD)a

86.1 (8.6)

84.6 (9.2)

86.9 (8.2)

2.29 (0.76, 3.83)

0.0034

  1. Note: Effect measure is expressed as amean difference with 95% CI, bdifference in median with 95% CI or crisk difference with 95% CI